Lifesci Capital Forecasts Surrozen FY2025 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for shares of Surrozen in a report issued on Thursday, November 13th. Lifesci Capital analyst P. Dolezal forecasts that the company will post earnings of ($3.12) per share for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. Lifesci Capital also issued estimates for Surrozen’s Q4 2025 earnings at ($1.59) EPS, Q1 2026 earnings at ($1.82) EPS, Q2 2026 earnings at ($1.84) EPS, Q3 2026 earnings at ($1.91) EPS, Q4 2026 earnings at ($1.15) EPS and FY2026 earnings at ($4.41) EPS.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The company had revenue of $0.98 million during the quarter.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Surrozen presently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Surrozen Stock Performance

Surrozen stock opened at $12.98 on Monday. The firm has a market cap of $111.24 million, a price-to-earnings ratio of -0.58 and a beta of 0.64. Surrozen has a 52-week low of $5.90 and a 52-week high of $18.17. The firm has a 50 day moving average price of $12.80 and a two-hundred day moving average price of $10.58.

Institutional Investors Weigh In On Surrozen

Several hedge funds and other institutional investors have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC acquired a new position in shares of Surrozen during the third quarter worth approximately $889,000. Acuta Capital Partners LLC increased its stake in Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after purchasing an additional 8,415 shares in the last quarter. Vanguard Group Inc. raised its holdings in Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after buying an additional 47,468 shares during the last quarter. Braidwell LP acquired a new position in Surrozen during the second quarter worth $1,252,000. Finally, Armistice Capital LLC bought a new position in shares of Surrozen in the second quarter valued at $536,000. Institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.